GIGA platforms go single cell !

GIGA platforms go single cell !

Following a training at the Karolinska Institute in Stockholm, a team of scientists at ULg’s GIGA, combining expertise in histology, NGS, imaging, and bioinformatics, is implementing Spatial Transcriptomics as a new service of GIGA-Technology platforms.

The advent of Next Generation Sequencing (NGS) technologies has boosted genomic sciences to unprecedented perspectives with the characterization of an impressive number of genomes for various organisms and individuals, healthy or affected. NGS technologies have also been extensively used to determine transcriptomic signatures for specific tissues or in particular conditions. So far, these strategies have mostly been applied to tissues or organs, which usually correspond to complex mixtures of very different types of cells. Although very informative already, such “bulk” sequencing however prevents from apprehending the cellular complexity and from identifying subtle modifications happening in specific cell types, conditions or locations in a tissue. Over the past couple of years have emerged technologies enabling to overcome these limitations: single cell RNA sequencing (scRNA-seq) and Spatial Transcriptomics.

In scRNA-seq, cells from a complex heterogeneous mixture are first isolated by capture in micro-wells or through encapsulation in micro-droplets using microfluidic devices (Gawad C. et al., Nature reviews: genetics, 17, 175-188. (2016)). Thousands of cells can then be sequenced in parallel thanks to the incorporation during cDNA synthesis of cell-specific DNA barcodes as well as unique molecular identifiers. Once traced back to their originating cells, the sequencing reads can be used to identify the different cell types present in the initial mixture irrespective of any preconceived composition. Given the increasing popularity of scRNA-seq, several alternatives have been developed and commercialized. The GIGA-Genomics platform has acquired a 10X Chromium System enabling to generate transcriptomic profiles for thousands of single cells in a single run.

Related articles

PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

Liège (Belgium), 21st January 2019. PDC*line Pharma is delighted to announce, that the company is now accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for the Quality Control and Release activities of its anticancer agent PDC*lung, intended for the treatment of patients with lung cancer.  PDC*line Pharma is developing a new

Read more
PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

First Congress in Health Simulation

The Medical Simulation Center of the University of Liège organizes its first congress in Health Simulation: “Towards evidence-based simulation”. Event will be held on Thursday, March 28th, 2019 in the faculty of medicine amphitheatres of Liège University, located on Sart-Tilman campus. Several themes will be discussed: Evidence-based Innovations and advances in simulation Medical education –

Read more
First Congress in Health Simulation

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials